Pharma Focus Europe
ThermoFisher Scientific - Custom and Bulks

Avance Clinical and Ryght Collaborate to Introduce Innovative GenAI Technologies in Clinical Research Networks

Wednesday, February 21, 2024

Ryght, a trailblazer in generative artificial intelligence (GenAI) technology for the life science industry, has unveiled a strategic collaboration with Avance Clinical, the foremost specialist Australian and US CRO (Clinical Research Organization) facilitating quality clinical trials in Australia, New Zealand, and North America for global biopharma firms.

The partnership entails Avance Clinical leveraging Ryght's advanced GenAI technology, which employs various large language models (LLMs) tailored for the industry to analyze real-time data streams and intricate data sets, delivering actionable insights to clinical research teams. Through integrating Ryght's sophisticated platform, Avance aims to enhance its GenAI capabilities, empowering its biopharma partners to streamline daily workflows and foster innovation within the biopharmaceutical domain.

Ryght, expressed, "Our partnership with Avance Clinical enables the adaptable GenAI platform to accelerate the productivity of its workforce and research networks by catering to their specific needs, such as simplifying the labor-intensive tasks like extensive documentation required for clinical development. This collaboration signifies a significant milestone in advancing GenAI-powered solutions within the CRO and biopharma sector. By pooling collective knowledge and resources, both entities are poised to leave a lasting imprint on the future of healthcare."

Avance Clinical, renowned for its commitment to innovation and improving patient care through cutting-edge technologies, will integrate the Ryght platform into its research networks to optimize workflows, enhance operational efficiency, and unlock new avenues for collaboration and discovery.

Avance Clinical, expressed enthusiasm about the collaboration, stating, "We are excited to partner with Ryght and leverage their GenAI platform to enhance our clinical trial processes. Ryght's innovative technology seamlessly aligns with our ethos of innovation and excellence. Through AI application, we aim to further assist our biotech clients in developing transformative therapeutics to address unmet medical needs."

To learn more about how GenAI is revolutionizing the landscape of CROs and clinical development by expediting innovation and tackling long-standing challenges, RSVP for Ryght's upcoming LinkedIn Live discussion on Thursday, Feb. 29, 2024. Interested individuals can also access a free beta version of Ryght at www.ryght.ai.

 

Source: prnewswire.com

magazine-slider-img
Get instant
access to our latest e-book
patheon - Mastering API production at every scaleLab Indonesia 20247th Pharma Packaging and Labelling Forum 2024Future Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing PharmaWorld Vaccine Congress Europe 2024